RPg Family Wealth Advisory LLC decreased its holdings in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH – Get Rating) by 51.5% in the 1st quarter, Holdings Channel reports. The firm owned 1,500 shares of the medical equipment provider’s stock after selling 1,594 shares during the period. RPg Family Wealth Advisory LLC’s holdings in Lantheus were worth $83,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors also recently modified their holdings of the company. City State Bank purchased a new position in shares of Lantheus during the fourth quarter worth about $83,000. Nisa Investment Advisors LLC purchased a new stake in Lantheus in the fourth quarter worth approximately $144,000. Fairfield Bush & CO. purchased a new stake in Lantheus in the first quarter worth approximately $177,000. Pinnacle Associates Ltd. purchased a new stake in Lantheus in the fourth quarter worth approximately $204,000. Finally, Baker Tilly Wealth Management LLC purchased a new stake in Lantheus in the first quarter worth approximately $220,000. Hedge funds and other institutional investors own 97.14% of the company’s stock.
Insider Activity at Lantheus
In related news, CEO Mary Anne Heino sold 12,276 shares of the company’s stock in a transaction on Monday, May 9th. The stock was sold at an average price of $61.19, for a total value of $751,168.44. Following the sale, the chief executive officer now directly owns 695,115 shares of the company’s stock, valued at $42,534,086.85. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. In other Lantheus news, CEO Mary Anne Heino sold 12,276 shares of the company’s stock in a transaction dated Monday, May 9th. The shares were sold at an average price of $61.19, for a total value of $751,168.44. Following the sale, the chief executive officer now owns 695,115 shares in the company, valued at $42,534,086.85. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CAO Andrea Sabens sold 386 shares of the company’s stock in a transaction dated Friday, July 15th. The stock was sold at an average price of $69.12, for a total transaction of $26,680.32. Following the completion of the sale, the chief accounting officer now owns 64,255 shares in the company, valued at approximately $4,441,305.60. The disclosure for this sale can be found here. Insiders have sold 26,798 shares of company stock worth $1,676,307 over the last 90 days. 1.60% of the stock is owned by company insiders.
Analysts Set New Price Targets
Lantheus Price Performance
LNTH stock opened at $78.57 on Friday. The company has a current ratio of 1.85, a quick ratio of 1.64 and a debt-to-equity ratio of 0.27. Lantheus Holdings, Inc. has a 12-month low of $22.20 and a 12-month high of $81.43. The stock has a market capitalization of $5.39 billion, a price-to-earnings ratio of 182.72 and a beta of 0.79. The firm’s 50-day moving average price is $67.85 and its two-hundred day moving average price is $55.56.
Lantheus (NASDAQ:LNTH – Get Rating) last posted its earnings results on Thursday, August 4th. The medical equipment provider reported $0.89 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.64 by $0.25. Lantheus had a return on equity of 28.88% and a net margin of 4.88%. The firm had revenue of $223.80 million for the quarter, compared to analysts’ expectations of $204.51 million. During the same period in the previous year, the firm earned $0.11 earnings per share. The business’s revenue was up 121.4% compared to the same quarter last year. As a group, equities analysts predict that Lantheus Holdings, Inc. will post 2.84 earnings per share for the current year.
Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, a microbubble ultrasound enhancing agent used in ultrasound exams of the heart; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent; Thallium-201 to detect cardiovascular disease; and Gallium-67 to detect various infections and cancerous tumors.
- Get a free copy of the StockNews.com research report on Lantheus (LNTH)
- MarketBeat: Week in Review 8/1 – 8/5
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Cronos Group Inc’s Revenues Are Up, Is It Time to Buy?
- Why Apple Could Be At All-Time Highs By Year End
- Beyond Meat Is Not Beyond Hope, And It’s Cheap
Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.